In vitro cytogenetic assessment and comparison of vildagliptin and sitagliptin.
Antidiabetic
Comparison
In vitro genotoxicity
Sitagliptin
Vildagliptin
Journal
Cytotechnology
ISSN: 0920-9069
Titre abrégé: Cytotechnology
Pays: United States
ID NLM: 8807027
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
18
02
2019
accepted:
14
09
2019
pubmed:
27
9
2019
medline:
27
9
2019
entrez:
27
9
2019
Statut:
ppublish
Résumé
Vildagliptin and sitagliptin are commonly used antidiabetic drugs. Chromosomal aberration (CA), sister chromatid exchange (SCE) and cytokinesis-block micronucleus (CBMN) assays were employed to assess and compare cytotoxic and genotoxic effects of these drugs. Peripheral lymphocytes were exposed to 125 μg/ml, 250 μg/ml and 500 μg/ml of vildagliptin and 250 μg/ml, 500 μg/ml and 1000 μg/ml of sitagliptin for 24 h and 48 h with and without exogenous metabolic activation. At the end of the study, it was determined that these drugs and their metabolites had no genotoxic effects on CA, SCE and CBMN. On the other hand, parallel to the increase in dose, vildagliptin showed weak cytotoxicity on the mitotic index, and depending on its increase in dose; sitagliptin caused potential cytotoxicity and cytostatic effect on the mitotic index, nuclear division index and proliferation index. Due to their cytotoxic and cytostatic potential, these drugs inhibit cell proliferation.
Identifiants
pubmed: 31555935
doi: 10.1007/s10616-019-00345-y
pii: 10.1007/s10616-019-00345-y
pmc: PMC6874628
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1063-1077Subventions
Organisme : Ondokuz Mayis Üniversitesi
ID : PYO.TIP.1904-15.030
Références
Curr Med Chem. 2011;18(31):4753-60
pubmed: 21919850
Chromosoma. 1982;86(3):375-82
pubmed: 6184205
Food Chem Toxicol. 2015 Sep;83:146-50
pubmed: 26115598
Drug Chem Toxicol. 2015 Jan;38(1):57-62
pubmed: 24641298
Postgrad Med. 2017 Apr;129(3):352-365
pubmed: 27882816
J Diabetes Investig. 2014 May 4;5(3):251-64
pubmed: 24843770
Food Chem Toxicol. 2017 Aug;106(Pt B):600-608
pubmed: 27554597
J Clin Diagn Res. 2015 Dec;9(12):FC14-6
pubmed: 26816911
Mutat Res. 2000 Nov 20;455(1-2):81-95
pubmed: 11113469
Cancer Immunol Immunother. 2009 Nov;58(11):1723-47
pubmed: 19557413
Curr Med Res Opin. 2007 Apr;23(4):945-52
pubmed: 17407651
Int J Cancer. 2013 Nov 15;133(10):2498-503
pubmed: 23649733
Ann Clin Lab Sci. 1994 Sep-Oct;24(5):387-95
pubmed: 7818234
Nat Rev Dis Primers. 2015 Jul 23;1:15019
pubmed: 27189025
Anticancer Drugs. 1993 Dec;4(6):637-40
pubmed: 8298163
Environ Toxicol. 2014 Jun;29(6):631-41
pubmed: 22730181
Biochimie. 2006 Nov;88(11):1515-31
pubmed: 16919864
Genes Environ. 2016 Oct 1;38:18
pubmed: 27733885
Mutat Res. 2013 Sep 18;757(1):31-5
pubmed: 23859957
Mutagenesis. 2009 Jul;24(4):341-9
pubmed: 19535363
Diabetes Obes Metab. 2012 Jul;14(7):579-85
pubmed: 22171706
Exp Cell Res. 1960 Sep;20:613-6
pubmed: 13772379
Drugs. 2014 Feb;74(2):223-42
pubmed: 24407560
Food Chem Toxicol. 2018 Feb;112:235-241
pubmed: 29317328
Mutat Res. 1996 Sep;365(1-3):147-59
pubmed: 8898995
Hum Genet. 1984;67(3):264-9
pubmed: 6469241
Eur J Pharm Sci. 2017 Mar 30;100:17-24
pubmed: 28065853
Drug Resist Updat. 2007 Feb-Apr;10(1-2):13-29
pubmed: 17303468
Leukemia. 2013 Jun;27(6):1236-44
pubmed: 23318959
Am J Obstet Gynecol. 2004 Aug;191(2):398-407
pubmed: 15343213
Sci Rep. 2017 Apr 13;7:46628
pubmed: 28406239
Mutat Res. 2001 Apr 5;491(1-2):163-72
pubmed: 11287309
Mutat Res. 1975 Jun;31(3):135-48
pubmed: 1128546
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21
pubmed: 20554718